for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allergan plc

AGN.N

Latest Trade

200.15USD

Change

1.41(+0.71%)

Volume

1,143,654

Today's Range

198.02

 - 

200.40

52 Week Range

114.27

 - 

202.22

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
198.74
Open
198.15
Volume
1,143,654
3M AVG Volume
47.47
Today's High
200.40
Today's Low
198.02
52 Week High
202.22
52 Week Low
114.27
Shares Out (MIL)
329.00
Market Cap (MIL)
65,385.86
Forward P/E
--
Dividend (Yield %)
1.49

Next Event

Q1 2020 Allergan plc Earnings Release

Latest Developments

More

CMA Issues Supplementary Objections On Probe Relating To Supply Of Hydrocortisone Tablets In UK

Allergan Reports Q4 Loss Per Share Of $0.97

AbbVie Expects 2020 Skyrizi Revenue Of ~$1.2 Bln And Rinvoq Revenue Of ~$500 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allergan plc

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.

Contact Info

Clonshaugh Business And Technology Park

+353.21.65235000

https://www.allergan.com/

Executive Leadership

Brenton L. Saunders

Chairman of the Board, President, Chief Executive Officer

Matthew M. Walsh

Chief Financial Officer, Executive Vice President

Karen Lee Ling

Chief Human Resource Officer, Executive Vice President

A. Robert D. Bailey

Executive Vice President, Chief Legal Officer and Corporate Secretary

William J. Meury

Executive Vice President, Chief Commercial Officer

Key Stats

2.84 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

15.9K

2018

15.8K

2019

16.1K

2020(E)

16.0K
EPS (USD)

2017

16.350

2018

16.690

2019

17.640

2020(E)

17.376
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.06
Price To Book (MRQ)
1.12
Price To Cash Flow (TTM)
82.14
Total Debt To Equity (MRQ)
38.93
LT Debt To Equity (MRQ)
31.14
Return on Investment (TTM)
-5.86
Return on Equity (TTM)
-5.36

Latest News

Latest News

Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan

A group of unions and consumer groups wrote to U.S. antitrust enforcers on Tuesday to oppose a proposed remedy that could lead to U.S. approval for AbbVie Inc's <ABBV.N> planned purchase of Allergan Plc <AGN.N>.

BRIEF-Allergan Reports Q4 Loss Per Share Of $0.97

* ALLERGAN REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

New drugs contribute to AbbVie's upbeat 2020 view; shares hit year-high

AbbVie Inc <ABBV.N> on Friday forecast full-year earnings well above Wall Street estimates, as the U.S. drugmaker looks to new treatments and its pending acquisition of Allergan Plc <AGN.N> to drive growth beyond 2023, when its cash cow Humira loses patent protection.

AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys

U.S. drugmaker AbbVie's <ABBV.N> $63 billion tie-up with Allergan <AGN.N> is getting help from Nestle <NESN.S> and AstraZeneca <AZN.L> buying up products the Irish-domiciled company is shedding to placate regulators.

Nestle buys Allergan business to expand in medical nutrition

Swiss food giant Nestle <NESN.S> on Monday bulked up its medical nutrition business by buying Allergan's <AGN.N> Zenpep, a product for people whose pancreases do not provide enough enzymes to properly digest fats, proteins and sugars.

Nestle buys Allergan business to expand in medical nutrition

Nestle on Monday said it is buying Allergan's Zenpep to expand in medical nutrition with a product for people who cannot digest food properly because their pancreas does not provide enough enzymes to break down fat, protein, and carbohydrates.

EU clears AbbVie takeover of Allergan subject to conditions

The European Commission said on Friday it had approved U.S. drugmaker AbbVie's <ABBV.N> planned $63 billion (48.24 billion pounds) acquisition of Botox-maker Allergan <AGN.N>, subject to conditions.

BRIEF-Ironwood, Allergan Announce Settlement Resolving Linzess (Linaclotide) Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

Allergan signs $750 million settlement with purchasers of Alzheimer's drug Namenda

Purchasers of Allergan Plc's Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer's medication off the market.

Allergan's acute migraine treatment wins U.S. FDA approval

The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc's drug for relieving migraine headaches after their onset.

Allergan's acute migraine treatment wins U.S. FDA approval

The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc's drug for treating acute migraine in adults.

AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

AbbVie Inc <ABBV.N> on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc <AGN.N>.

AbbVie says multiple parties vying for assets related to Allergan deal approval

AbbVie Inc <ABBV.N> said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc <AGN.N>.

Allergan settles Alzheimer's therapy lawsuit for $750 million

Allergan Plc would pay $750 million to settle a class action lawsuit from a group of direct purchasers of Alzheimer's disease therapy Namenda, the drugmaker said, in a resolution to the litigation that was set to face trial on Monday.

Allergan settles Alzheimer's therapy lawsuit for $750 million

Allergan Plc said on Monday it had settled a class action lawsuit brought by a group of direct purchasers of Alzheimer's disease therapy Namenda, resolving the litigation that was set to face trial this month.

FTC requests AbbVie, Allergan for more information on $63 billion deal

The U.S. Federal Trade Commission (FTC) has requested for more information from AbbVie Inc <ABBV.N> and botox maker Allergan Plc <AGN.N> on their $63 billion deal, the companies said on Friday.

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's <ABBV.N> planned $63 billion purchase of Botox maker Allergan...

Drugmakers Endo, Allergan agree to $15 million in settlements in major opioid case

Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Evolus reports sales of its Botox rival ahead of expectations

Medical aesthetics company Evolus Inc <EOLS.O> on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's <AGN.N> Botox, which has dominated the medical aesthetics market for more than a decade.

Evolus says launch of its Botox rival ahead of its expectations

Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up